Sample output 2

The table below represents a ranked list of terms extracted automatically from a corpus of PubMed abstracts about chronic obstructive pulmonary disease. Term variants grouped together in the second column represent lowercased versions of all surface forms found in the corpus. For each term, the variants are ordered by their frequency of occurrence in the corpus. The score in the rightmost column is called termhood and is calculated as a function of frequency and length (in tokens minus stopwords). Alternatively, you may view the results as a dendrogram produced by the clustering algorithm described in this paper.

Rank Term variants Score
1 copd
chronic obstructive pulmonary disease
 681.7536
2 pulmonary disease
 340.4535
3 patients with copd
copd patients
patients with chronic obstructive pulmonary disease
patients with chronic obstructive pulmonary diseases
 168.5033
4 copd exacerbation
copd exacerbations
exacerbations of chronic obstructive pulmonary disease
exacerbations of copd
chronic obstructive pulmonary disease exacerbations
exacerbation of chronic obstructive pulmonary disease
exacerbation of copd
 76.9604
5 patients with milder disease
 73.4736
6 aecopd
acute exacerbation of copd
acute exacerbations of chronic obstructive pulmonary disease
acute exacerbations of copd
 39.4187
7 acute exacerbation
acute exacerbations
 34.5088
8 qol
quality of life
 24.5572
9 pr
pulmonary rehabilitation
effectiveness of pr
 22.6606
10 stable chronic obstructive pulmonary disease
stable copd
 18.3936
11 chronic obstructive lung disease
 16.4045
12 copd severity
severity of copd
 15.7725
13 gold
global initiative for chronic obstructive lung disease
 15.2300
14 cb
chronic bronchitis
 13.9496
15 acute exacerbation of cb
aecb
acute exacerbation of chronic bronchitis
 12.4766
15 or
odds ratio
 12.4766
16 airway smooth muscle
asm
 12.0847
16 health-related quality of life
hr-qol
hrql
health-related qol
 12.0847
17 risk of copd
risk of chronic obstructive pulmonary disease
 11.2661
18 lung function
 10.8304
19 patients with stable copd
stable copd patients
 10.7506
20 stable disease
 10.7438
21 frc
functional residual capacity
 9.8875
22 mmse
mini mental state examination
 9.7041
23 copd guideline
 9.6566
23 pathogenesis of chronic obstructive pulmonary disease
pathogenesis of copd
copd pathogenesis
pathogenesis of chronic obstructive pulmonary diseases
 9.6566
23 treatment of chronic obstructive pulmonary disease
treatment of copd
 9.6566
24 airway inflammation
 9.0109
25 course of copd
course of chronic obstructive pulmonary diseases
 8.8519
26 at
anaerobic threshold group
 8.7889
26 mip
maximal inspiratory pressure
 8.7889
27 exercise capacity
 8.4911
27 respiratory questionnaire
 8.4911
28 ic
inspiratory capacity
 8.3178
29 incidence of chronic obstructive pulmonary disease copd
incidence of copd
incident chronic obstructive pulmonary disease
 8.0472
29 prevalence of copd
copd prevalence
prevalent copd
 8.0472
30 control group
control groups
 7.6246
30 ics
inhaled corticosteroids
 7.6246
30 health status
hs
 7.6246
31 desaturator copd patients
copd desaturator patients
 7.1670
32 disease severity
 7.0470
33 patients with asthma
asthma patients
 6.9315
33 uchl1
ubiquitin carboxyl-terminal hydrolase l1
 6.9315
33 hi
high-intensity group
 6.9315
33 nppv
noninvasive positive pressure ventilation
 6.9315
34 risk factors
risk factor
 6.8325
35 mat
multifocal atrial tachycardia
 6.5917
35 imv
invasive mechanic ventilation
 6.5917
35 pr program
pulmonary rehabilitation programs
 6.5917
36 development of copd
copd development
development of chronic obstructive pulmonary disease
 6.4378
36 hospitalisation for copd
copd hospitalisation
 6.4378
37 acute bronchitis
 6.4116
38 rehabilitation program
 6.3770
39 bacterial infection
bacterial infections
 6.2383
39 expiratory volume
 6.2383
39 respiratory rate
rr
 6.2383
40 mechanical ventilation
 6.0650
40 niv
non-invasive ventilation
 6.0650
41 healthy subjects
 5.8918
42 bal
bronchial lavage
 5.8224
43 ba
bronchial asthma
 5.5452
43 functional limitations in chinese elders
 5.5452
43 slpi
secretory leukocyte protease inhibitor
 5.5452
44 bmd
bone mineral density
 5.4931
44 tdi
transitional dyspnoea index
 5.4931
45 frequency of copd exacerbation
 5.3753
45 non-desaturator copd patients
 5.3753
46 peroxynitrite inhibitory activity
 5.1269
47 functional limitations
 5.0253
48 airflow obstruction
 4.8520
48 co
cardiac output
cardiac outputs
 4.8520
48 expiratory r
 4.8520
48 rv
residual volume
 4.8520
49 cases with copd
 4.8283
50 sgrq score
 4.6787
51 lung volumes
lung volume
 4.6210
52 anaerobic threshold
 4.5055
53 body mass index
 4.3944
53 bos
bronchiolitis obliterans syndrome
 4.3944
53 chronic nonproductive cough
 4.3944
53 tumor necrosis factor-alpha
 4.3944
53 inhalation of thermal water
thermal water inhalations
 4.3944
53 slt
single lung transplantation
 4.3944
53 regulation of muscle mass
muscle mass regulation
 4.3944
54 airway smooth muscle cells
 4.1589
54 crq
chronic respiratory disease questionnaire
 4.1589
54 confidence interval
 4.1589
54 er
emergency room
 4.1589
54 exercise training
training exercises
 4.1589
54 plasma ghrelin
 4.1589
54 group of patients
patient group
 4.1589
54 heart rate
hr
heart rates
 4.1589
54 sv
sham ventilation
 4.1589
55 heart failure
 4.0203
56 dyspnoea score
dyspnea scores
 3.9278
57 disease course
 3.9278
58 medical research council
mrc
 3.8451
59 leg activity
 3.4657
59 hospital admission
 3.4657
59 airflow limitation
 3.4657
59 asthmatic patients
 3.4657
59 borg score
 3.4657
59 ph
pulmonary hypertension
 3.4657
59 inhalation technique
 3.4657
59 walking tests
 3.4657
60 6-min walking test
6-min walking tests
 3.2958
60 treatment of acute exacerbation
treatment of acute exacerbations
treatments for acute exacerbation
 3.2958
60 vha
veterans health administration
 3.2958
60 bpv
blood pressure variability
 3.2958
60 bal il-8
 3.2958
60 maximal exercise capacity
 3.2958
60 ivc
inferior vena cava
 3.2958
60 chronic respiratory questionnaire
 3.2958
60 verbal descriptors of dyspnea
 3.2958
60 implementation of standing orders
 3.2958
60 normal weight patients
 3.2958
60 snps
single nucleotide polymorphisms
 3.2958
60 total sgrq score
total sgrq scores
 3.2958
61 total scores
 3.2924
61 thermal water
 3.2924
62 hedgehog-interacting protein
hip
 3.2347
62 induced sputum
 3.2347
63 associations with copd
 3.2189
63 exercise in copd
 3.2189
63 copd group
copd groups
 3.2189
63 management of copd
 3.2189
63 mechanisms for chronic obstructive pulmonary disease
 3.2189
63 copd disease stages
copd stage
 3.2189
64 control subjects
 3.1192
65 physical activity
 2.7726
65 regression analysis
 2.7726
65 measurement b
 2.7726
65 breathing pattern
 2.7726
65 ipratropium bromide
 2.7726
65 respiratory burst of sputum cells
 2.7726
65 vena cava
 2.7726
65 disease progression
 2.7726
65 dns
district nurses
 2.7726
65 intensity level of dyspnea
intensity levels of dyspnea
intensity of dyspnea
 2.7726
65 exacerbation in patients
exacerbations in patients
patients with frequent exacerbations
 2.7726
65 vascular function
 2.7726
65 postimplementation group
 2.7726
65 preimplementation group
 2.7726
65 hospital mortality
 2.7726
65 length of stay
los
 2.7726
65 maternal smoking
 2.7726
65 pm
particulate matter
 2.7726
65 outcomes for patients
outcomes of patients
 2.7726
65 personal pm2
 2.7726
65 quadriceps weakness
 2.7726
65 respiratory status
 2.7726
66 sputum cells
 2.5415
66 oxygen saturation
 2.5415
67 non-productive cough
 2.4260
67 muscle mass
 2.4260
68 airway surface dehydration
 2.1972
68 eosinophilic airway inflammation
 2.1972
68 common carotid arteries
 2.1972
68 mdb
mental deterioration battery
 2.1972
68 sbm
subepithelial basement membrane
 2.1972
68 dbp
diastolic blood pressure
 2.1972
68 pursed lip breathing
 2.1972
68 bal fluid
 2.1972
68 uct
urgent care team
 2.1972
68 chronic mucus hypersecretion
 2.1972
68 chd
coronary heart disease
 2.1972
68 decline in lung function
 2.1972
68 domiciliary oxygen therapy
 2.1972
68 dyspnea during exercise
 2.1972
68 hip gene
 2.1972
68 health service utilization
 2.1972
68 hs subscales
 2.1972
69 txa2
thromboxane a2
 2.0794
69 controls of similar age
 2.0794
69 first-line agents
 2.0794
69 room air
 2.0794
69 airway functions
 2.0794
69 asthma severity
 2.0794
69 bacterial concentrations
bacterial concentration
 2.0794
69 betaenac-overexpressing mice
 2.0794
69 bone biomarkers
 2.0794
69 bronchial biopsies
 2.0794
69 long-acting bronchodilators
 2.0794
69 conventional care
 2.0794
69 moraxella catarrhalis
 2.0794
69 neuroendocrine cells
neuroendocrine cell
 2.0794
69 smoking cessation
 2.0794
69 chronic inflammation
 2.0794
69 chronic smokers
 2.0794
69 cov
coefficient of variation
 2.0794
69 cognitive dysfunction
 2.0794
69 serum concentrations
 2.0794
69 healthy controls
 2.0794
69 normal controls
 2.0794
69 controlled trial
controlled trials
 2.0794
69 oral corticosteroids
 2.0794
69 depressive symptoms
 2.0794
69 verbal descriptors
 2.0794
69 dosages of formoterol
formoterol dosages
 2.0794
69 management of exacerbations
 2.0794
69 mechanism for exacerbations
 2.0794
69 submaximal exercise
 2.0794
69 expiratory flow
 2.0794
69 expiratory resistance
 2.0794
69 flow limitation
 2.0794
69 haemophilus influenzae
 2.0794
69 health resources
 2.0794
69 natural history
 2.0794
69 hyperventilation-evoked hyperinflation
 2.0794
69 renal impairment
 2.0794
69 systemic inflammation
 2.0794
69 nitrogen oxides
 2.0794
69 oxidative stress
 2.0794
69 patients after salmeterol
 2.0794
69 patients after tiotropium
 2.0794
69 underweight patients
 2.0794
69 personal smoking
 2.0794
69 streptococcus pneumoniae
 2.0794
69 respiratory symptoms
 2.0794
69 respiratory system
 2.0794
69 tachycardia threshold
 2.0794
69 tidal volume
 2.0794
70 severity of copd exacerbations
 1.7918
71 respiratory burst
 1.7329
71 feno measurements
 1.7329
71 mucus hypersecretion
 1.7329
72 chronic obstructive lung disease stage
 1.6094
73 diagnostic accuracy
 1.3863
73 strain acquisition
 1.3863
73 advanced disease
 1.3863
73 adverse events
 1.3863
73 airways of patients
 1.3863
73 alpha1-at polymerization
 1.3863
73 annual rate
 1.3863
73 antimicrobial therapy
 1.3863
73 ra
right atrium
 1.3863
73 baseline characteristics
 1.3863
73 inhaled beta
 1.3863
73 breathing intensity
 1.3863
73 bronchial infections
 1.3863
73 c. pneumoniae
 1.3863
73 cell size
 1.3863
73 tau ch50
 1.3863
73 cigarette smoke
cigarette smoking
 1.3863
73 clinical outcomes
 1.3863
73 clinical trial
clinical trials
 1.3863
73 community pharmacies
 1.3863
73 conventional ventilation
 1.3863
73 productive cough
 1.3863
73 mrc score
 1.3863
73 spontaneous course
 1.3863
73 flow-volume curve
 1.3863
73 primary disease
 1.3863
73 family doctor
 1.3863
73 reduction in exacerbations
 1.3863
73 mrna expression
mrna expressions
 1.3863
73 respiratory failure
 1.3863
73 treatment with fsc
 1.3863
73 il-27 gene
 1.3863
73 lung hyperinflation
 1.3863
73 inflammatory mediators
 1.3863
73 inhalation treatment
 1.3863
73 intubated patients
 1.3863
73 japanese patients
 1.3863
73 outcome measures
 1.3863
73 training program
 1.3863
73 secondary variables
 1.3863
73 stable state
 1.3863
74 repeatability of feno measurements
 1.0986
75 standard deviation
 0.6931
75 vascular endothelium
 0.6931
75 frequency of exacerbations
 0.6931
75 onset of exacerbation
 0.6931
75 potential for failure
 0.6931
75 hospital readmissions
 0.6931
75 iadl scale
 0.6931